Table 5. Correlation of plasma protein concentrations with the total protein amounts in the tumor tissues, tumor size, PFS, or OS among the GBM patients.
| Protein | Correlation coefficient (R2) | |||
|---|---|---|---|---|
| Total protein amount in tumor tissue | Tumor size | PFS | OS | |
| Up-regulated proteins | ||||
| C-reactive protein | 0.948*** | 0.495** | 0.214 | 0.108 |
| Complement component C9 | 0.661*** | 0.452** | 0.0638 | 0.00775 |
| Leucine-rich alpha-2-glycoprotein | 0.643*** | 0.534** | 0.0627 | 0.0197 |
| Alpha-1-antichymotrypsin | 0.357* | 0.184 | 0.00879 | 0.0220 |
| Apolipoprotein B-100 | 0.0323 | 0.225 | 0.134 | 0.0148 |
| Down-regulated proteins | ||||
| Gelsolin | 0.0166 | 0.00188 | 0.253 | 0.330* |
| Apolipoprotein A-IV | 0.00450 | 0.0903 | 0.113 | 0.163 |
| Ig alpha-1 chain C region | 0.00187 | 0.0166 | 0.00999 | 0.00676 |
Pearson correlational analysis was used to compare plasma protein concentrations and the total protein amounts in the tumor tissues, tumor size, progression-free survival time (PFS), or overall survival time (OS) among the glioblastoma (GBM) patients. We multiplied cytosol protein concentrations by tumor size to calculate the total protein amounts in the tumor tissues.
*, p < 0.05
**, p < 0.01
***, p < 0.001.